EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy

Jie Zhu, Liting Huang, Suzhen Bi, WeiKaixin Kong, Wanting Feng, Yingjia Li, Zhengwei Xie iD, Peipei Shan iD, Sujie Zhu iD

Advanced Science · 2025

DOI: 10.1002/advs.202503979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jie Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, 266071, P. R. C…. Hauptthemen laut MEDLINE: Fulvestrant, Vitiligo, Immunotherapy, Melanoma. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation of China, Youth Scholars of Higher Education of Shandong Province, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has revolutionized cancer treatment; however, only 10–30% of patients experience durable survival benefits, while most malignancies remain resistant. In melanoma, vitiligo‐like depigmentation is a frequent and generally mild immune‐related adverse event, whose presence correlates positively with enhanced antitumor immune responses and prolonged patient survival. By performing comparative analyses between vitiligo and melanoma, we established a biomarker panel—designated the vitiligo signature (VGS)—that differentiates “cold” from “hot” tumors with high accuracy. Leveraging a deep learning–based efficacy prediction system (DLEPS), we identified and validated Fulvestrant as a candidate capable of enhancing anti–programmed cell death ligand 1 (PD L1) therapy in preclinical models. Single cell RNA sequencing revealed that Fulvestrant expanded cytotoxic T cell populations, while immunofluorescence and flow cytometry confirmed markedly increased CD8⁺ T cell infiltration into tumor tissue. Mechanistic investigations demonstrated that Fulvestrant activates the C─C motif chemokine 5 (CCL5), major histocompatibility complex class I (MHC I), and type II interferon (IFN II) signaling pathways, thereby potentiating antitumor immunity. Collectively, our study introduces a precision approach for patient stratification in immunotherapy and highlights Fulvestrant as a promising component of immunotherapy based combination strategies warranting clinical evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FulvestrantVitiligoImmunotherapyMelanomaHumansMiceAnimalsFemaleCell Line, Tumor

Stichwörter der Autor:innen

Fulvestrantimmunotherapyvitiligo

Substanzen

Fulvestrant

Autor:innen und Institutionen

  • Institute of Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, 266071, P. R. China.
  • Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, 00100, Finland.
  • Peking University International Cancer Institute, Peking University‑Yunnan Baiyao International Medical Research Center, State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmac…

ORCID-Profile: Zhengwei Xie, Peipei Shan, Sujie Zhu

Förderung

  • National Science Foundation of China
  • Youth Scholars of Higher Education of Shandong Province
  • Natural Science Foundation of Shandong Province
  • National Natural Science Foundation of China

Zitieren

APA

Zhu, J., Huang, L., Bi, S., Kong, W., Feng, W., Li, Y., Xie, Z., Shan, P., & Zhu, S. (2025). Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy. Advanced Science. https://doi.org/10.1002/advs.202503979

Vancouver

Zhu J, Huang L, Bi S, Kong W, Feng W, Li Y, et al. Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy. Advanced Science. 2025. doi:10.1002/advs.202503979

BibTeX
@article{Zhu2025,
  author = {Zhu, Jie and Huang, Liting and Bi, Suzhen and Kong, WeiKaixin and Feng, Wanting and Li, Yingjia and Xie, Zhengwei and Shan, Peipei and Zhu, Sujie},
  title = {Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202503979}
}
Kostenlos starten →